TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22496437

Group type: EXPERIMENTAL
Intervention: Laser CCC (femtosecond laser-created continuous circular capsulotomy)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Manual CCC (manually performed continuous curvilinear capsulorrhexis)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Laser CCC
Number of subjects: 45
Study: 19909984

Group type: EXPERIMENTAL
Intervention: De Vega procedure
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Ring annuloplasty
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: De Vega + pericardial patch augmentation
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Ring annuloplasty + pericardial patch augmentation
Number of subjects: 210
Study: 18065019

Group type: EXPERIMENTAL
Intervention: Tegaderm Absorbent dressing
Number of subjects: 40

Group type: COMPARATOR
Intervention: Kaltostat dressing
Number of subjects: 40
Study: 16275125

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 12111109

Group type: EXPERIMENTAL
Intervention: Thioguanine (TG)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mercaptopurine (MP)
Number of subjects: 10
Study: 9892304

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 8636474

Group type: EXPERIMENTAL
Intervention: Box-only resin composite restorations
Number of subjects: 68
Study: 1975333

Group type: EXPERIMENTAL
Intervention: M37 vaccine (1 x 10(4) pfu)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Quadrivalent rotavirus vaccine (1 x 10(4) pfu each of serotype 3 RRV and human rotavirus‐RRV reassortants of serotypes 1, 2, and 4)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Balanced quadrivalent vaccine (1 x 10(4) pfu of serotype 1 and 3 components but 5 x 10(4) pfu of serotype 2 and 4 components)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 6791212

Group type: EXPERIMENTAL
Intervention: 0.50 ml/kg alcohol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1.0 ml/kg alcohol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.025 ml/kg alcohol
Number of subjects: 16
Study: 30586738

Group type: EXPERIMENTAL
Intervention: HbA1c ≥9.0% group
Number of subjects: 166

Group type: COMPARATOR
Intervention: HbA1c ≤7.0% group
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Positivity for ≥2 AAbs during DCCT
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Patients with ≥2 AAbs
Number of subjects: 166
Study: 28063245

Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-genetic dosing
Number of subjects: 0
Study: 26721142

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with acupoint embedding therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Simple acupuncture
Number of subjects: 120
Study: 22672130

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine (CHX) gluconate
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.03% triclosan + 0.025% sodium fluoride (NaF) + 12% ethyl alcohol
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.2% CHX + 0.3% triclosan + 0.3% NaF + 0.09% Zn chloride (ZnCl(2))
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 48
Study: 21169640

Group type: EXPERIMENTAL
Intervention: Phenobarbital (40 mg/kg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (no phenobarbital)
Number of subjects: 72
Study: 19669885

Group type: EXPERIMENTAL
Intervention: Evidence-based preventive interventions delivered by community teams through the PROSPER model
Number of subjects: 12000

Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 12000
Study: 17598009

Group type: EXPERIMENTAL
Intervention: Dalteparin (5,000 units/day until 20 weeks then 5,000 units q12h until 37 weeks or onset of labor)
Number of subjects: 91

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 91
Study: 15373928

Group type: EXPERIMENTAL
Intervention: HFA formoterol (12 microg)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: DPI formoterol (Foradil Aerolizer)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: CFC formoterol (Foradil CFC inhalers)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 11766869

Group type: EXPERIMENTAL
Intervention: Primary care anticoagulation management clinics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Secondary care anticoagulation management clinics
Number of subjects: 0
Study: 9922066

Group type: EXPERIMENTAL
Intervention: Hip Hop to Health program (4-year randomized controlled trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fat Reduction Intervention Trial in African-Americans (5-year trial)
Number of subjects: 0
Study: 7701277

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Eye tracking and autonomic responsivity
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Fluorodeoxyglucose positron emission tomography
Number of subjects: 22
Study: 2959426

Group type: EXPERIMENTAL
Intervention: Isradipine (2.5 mg b.i.d. with increments of 2.5 mg b.i.d. at weekly intervals)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Isradipine (2.5 to 10 mg b.i.d.)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 87
Study: 29635693

Group type: EXPERIMENTAL
Intervention: CO2 fractional laser treatment (one treatment each month) with topical 0.1% tacrolimus cream
Number of subjects: 45

Group type: COMPARATOR
Intervention: Topical 0.1% tacrolimus cream
Number of subjects: 45
Study: 26541905

Group type: EXPERIMENTAL
Intervention: Rapid-onset antiplatelet therapy (prasugrel or glycoprotein IIb-IIIa) in the prehospital setting
Number of subjects: 1452

Group type: EXPERIMENTAL
Intervention: Calling earlier (time from onset to ECG <120 minutes)
Number of subjects: 1452

Group type: EXPERIMENTAL
Intervention: Increasing time from diagnostic ECG to angiography (>90 minutes)
Number of subjects: 1452
Study: 25070482

Group type: EXPERIMENTAL
Intervention: New oral product of pioglitazone hydrochloride with increased hydroxypropyl cellulose (HPC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference listed drug (RLD) pioglitazone hydrochloride
Number of subjects: 0
Study: 23383006

Group type: EXPERIMENTAL
Intervention: Pictorial health warnings with increasing levels of warning intensity
Number of subjects: 3297

Group type: EXPERIMENTAL
Intervention: Pictorial health warnings
Number of subjects: 3297
Study: 20670726

Group type: EXPERIMENTAL
Intervention: Verapamil SR-based treatment
Number of subjects: 2180

Group type: EXPERIMENTAL
Intervention: Atenolol-based treatment
Number of subjects: 2180

Group type: COMPARATOR
Intervention: Both treatment strategies (Verapamil SR and Atenolol)
Number of subjects: 2180
Study: 18414838

Group type: EXPERIMENTAL
Intervention: Manual volumetry
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: FreeSurfer
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: IBASPM
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Manual volumetry and FreeSurfer
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Manual volumetry and IBASPM
Number of subjects: 41
Study: 16328200

Group type: EXPERIMENTAL
Intervention: Counselling
Number of subjects: 75

Group type: COMPARATOR
Intervention: Self-help manual
Number of subjects: 75
Study: 12744767

Group type: EXPERIMENTAL
Intervention: Warming therapy using a Warm Up device (n = 8)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard care (Control group)
Number of subjects: 33
Study: 11171790

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of vitamin C
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sequential infusions of dobutamine (Dob, Dob-2) without vitamin C
Number of subjects: 19
Study: 9394695

Group type: EXPERIMENTAL
Intervention: Treatment with metronidazole for E. histolytica
Number of subjects: 110

Group type: COMPARATOR
Intervention: Untreated children
Number of subjects: 110
Study: 8179146

Group type: EXPERIMENTAL
Intervention: Mixture of 2.5% thiopentone and 1% methohexitone (1:3 ratio)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Unmodified 1% methohexitone
Number of subjects: 120
Study: 3445589

Group type: EXPERIMENTAL
Intervention: Live combined mumps-measles vaccine (MMV)
Number of subjects: 648

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 648
Study: 31159752

Group type: EXPERIMENTAL
Intervention: Text message-enhanced clinical exercise rehabilitation program
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard clinical exercise rehabilitation program
Number of subjects: 36
Study: 28753217

Group type: EXPERIMENTAL
Intervention: Sutureless, flapless, and glueless intrascleral fixation of a standard three‐piece posterior chamber IOL
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 11
Study: 25128068

Group type: EXPERIMENTAL
Intervention: 4 % formalin
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 10 % formalin
Number of subjects: 120
Study: 24643489

Group type: EXPERIMENTAL
Intervention: Intervention group (n=816)
Number of subjects: 1224

Group type: COMPARATOR
Intervention: Control group (n=408)
Number of subjects: 1224
Study: 20817053

Group type: EXPERIMENTAL
Intervention: Strontium ranelate
Number of subjects: 2346

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2346
Study: 18205961

Group type: EXPERIMENTAL
Intervention: Propofol induction and maintenance
Number of subjects: 1158

Group type: EXPERIMENTAL
Intervention: Propofol induction with isoflurane/N2O
Number of subjects: 1158

Group type: EXPERIMENTAL
Intervention: Sevoflurane/N2O maintenance
Number of subjects: 1158

Group type: EXPERIMENTAL
Intervention: Sevoflurane/N2O alone
Number of subjects: 1158
Study: 16875952

Group type: EXPERIMENTAL
Intervention: Visually evoked potentials (VEP) with different visual stimulation tasks (checkerboard pattern and dartboard pattern)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher complexity of the checkerboard pattern and increasing visual field sections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frequency range of visual stimulation tasks
Number of subjects: 0
Study: 14652862

Group type: EXPERIMENTAL
Intervention: Koch's second approach for covariate adjustment in randomized clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Classical ANCOVA for continuous response
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correction factor for Koch's test statistic
Number of subjects: 0
Study: 11813764

Group type: EXPERIMENTAL
Intervention: Participation in a cardiac rehabilitation programme (CRP)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Not participating in a cardiac rehabilitation programme (CRP)
Number of subjects: 240
Study: 9106373

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day) with ERT
Number of subjects: 358

Group type: COMPARATOR
Intervention: Placebo with ERT
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day) without ERT
Number of subjects: 358

Group type: COMPARATOR
Intervention: Placebo without ERT
Number of subjects: 358
Study: 8385294

Group type: EXPERIMENTAL
Intervention: Azathioprine and prednisolone
Number of subjects: 106

Group type: COMPARATOR
Intervention: Cyclosporin and prednisolone
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Total material (both groups)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Total material (cessation of graft function as endpoint)
Number of subjects: 106
Study: 31482224

Group type: EXPERIMENTAL
Intervention: Galunisertib plus gemcitabine (GG)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Gemcitabine plus placebo (GP)
Number of subjects: 297
Study: 28619701

Group type: EXPERIMENTAL
Intervention: Web-based intervention (12 weeks, structured interactive sessions, therapist support upon request)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 180

Group type: COMPARATOR
Intervention: Wait-list control (unguided Web-based psycho-education)
Number of subjects: 180
Study: 25464897

Group type: EXPERIMENTAL
Intervention: Sodium picosulfate/magnesium citrate
Number of subjects: 200

Group type: COMPARATOR
Intervention: Polyethylene glycol with ascorbic acid
Number of subjects: 200
Study: 23421595

Group type: EXPERIMENTAL
Intervention: Dorsal preputial flap (group A)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Ventral dartos flap (group B)
Number of subjects: 130
Study: 21226937

Group type: EXPERIMENTAL
Intervention: Brief cognitive therapy (CT) while tapering antidepressants (AD)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Maintenance antidepressants (AD)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Combination of brief cognitive therapy (CT) with maintenance antidepressants (AD)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Economic evaluation (using a societal perspective)
Number of subjects: 276
Study: 18211999

Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 106

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 106
Study: 16429900

Group type: EXPERIMENTAL
Intervention: Absorbable 4‐0 braided polyglycolic acid sutures (Sentesorb) in the upper half of the incision
Number of subjects: 60

Group type: COMPARATOR
Intervention: 4‐0 nonabsorbable monofilamentous polypropylene suture (Monoplene) in the lower half of the incision
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lower half of the incision (both groups)
Number of subjects: 60
Study: 12739706

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily (o.d.)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg twice daily (b.i.d.)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study: 10561627

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (50 microg at 4-hour intervals for a maximum of 6 doses)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Foley catheter plus oxytocin (maximum dose of 36 mU/min)
Number of subjects: 200
Study: 8901793

Group type: EXPERIMENTAL
Intervention: Skim milk powder
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Calcium tablets
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Follow-up for milk powder group
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Follow-up for calcium tablet group
Number of subjects: 64

Group type: COMPARATOR
Intervention: Advice on dietary calcium supplementation and fat reduction
Number of subjects: 64
Study: 1667473

Group type: EXPERIMENTAL
Intervention: Anticalculus dentifrice containing 3.3% soluble pyrophosphate and 1.0% Gantrez copolymer in a 0.243% sodium fluoride/silica base
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo dentifrice containing 0.243% sodium fluoride in a silica base
Number of subjects: 0

Group type: COMPARATOR
Intervention: Customary oral hygiene procedures
Number of subjects: 0
Study: 6351894

Group type: EXPERIMENTAL
Intervention: 5% acyclovir ointment, applied five times a day for 5 days
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 13
Study: 31399139

Group type: EXPERIMENTAL
Intervention: Polyglycolic acid felt reinforcement
Number of subjects: 514

Group type: COMPARATOR
Intervention: Control (previous anastomosis methods)
Number of subjects: 514
Study: 27992396

Group type: EXPERIMENTAL
Intervention: Experimental manipulation of time spent in moderate-to-vigorous-intensity PA and sedentary time (Study 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulation of sedentary behavior while holding exercise constant (Study 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased exercise, decreased sedentary time, or both (Study 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurement of 3-month reliability for the pattern metrics (Study 4)
Number of subjects: 0
Study: 26856258

Group type: EXPERIMENTAL
Intervention: Telekit intervention
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 116
Study: 24846619

Group type: EXPERIMENTAL
Intervention: XR‐NTX + harm‐reduction counseling
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Placebo + harm‐reduction counseling
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Harm‐reduction counseling only
Number of subjects: 300

Group type: COMPARATOR
Intervention: Community-based, supportive-services-as-usual
Number of subjects: 300
Study: 22845494

Group type: EXPERIMENTAL
Intervention: Immediate release (IR) tapentadol 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate release (IR) tapentadol 75 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxycodone 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate release (IR) tapentadol (unspecified dosage)
Number of subjects: 0
Study: 19219261

Group type: EXPERIMENTAL
Intervention: Group 3x (G3) - 1 hour of physical exercise, 3 times/week for 20 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Group 5x (G5) - 1 hour of physical exercise, 5 times/week for 20 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control Group (CG) - encouraged to engage in a physical exercise program
Number of subjects: 40
Study: 17533178

Group type: EXPERIMENTAL
Intervention: Mometasone furoate aqueous nasal spray (50 microg per nostril per day) for 40 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Topical intranasal steroid treatment on alternate days for the first 2 weeks per month (group A1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Continued daily mometasone treatment for the first 2 weeks per month (group A2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mometasone treatment
Number of subjects: 60
Study: 15621710

Group type: EXPERIMENTAL
Intervention: Vegetal formulation of superoxide dismutase (SOD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: SOD group
Number of subjects: 20
Study: 11203778

Group type: EXPERIMENTAL
Intervention: ZP (restoration + zinc phosphate cement)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: GI (restoration + resin‐modified glass‐ionomer cement)
Number of subjects: 12

Group type: COMPARATOR
Intervention: C2 (no restoration and pH cycling)
Number of subjects: 12

Group type: COMPARATOR
Intervention: C1 (no restoration and no pH cycling)
Number of subjects: 12
Study: 9664089

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7530473

Group type: EXPERIMENTAL
Intervention: L-NMMA (2 mumol min-1) with bradykinin (100 pmol min-1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: L-NMMA (4 mumol min-1) with bradykinin (100 pmol min-1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: L-NMMA (2 mumol min-1) with substance P (1 pmol min-1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: L-NMMA (4 mumol min-1) with substance P (1 pmol min-1)
Number of subjects: 8
Study: 3292363

Group type: EXPERIMENTAL
Intervention: Azathioprine at a dose of 2 mg per kg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional combination regimen of azathioprine (1 mg per kg) with prednisolone
Number of subjects: 47

Group type: COMPARATOR
Intervention: Corticosteroid withdrawal
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Azathioprine group
Number of subjects: 47
Study: 31682162

Group type: EXPERIMENTAL
Intervention: Acumapimod 75 mg repeated single-dose on Days 1 and 6
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Oral prednisone 40 mg (10 days)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Acumapimod 20 mg single-dose
Number of subjects: 183
Study: 28903510

Group type: EXPERIMENTAL
Intervention: RAL (400 mg twice daily)
Number of subjects: 39

Group type: COMPARATOR
Intervention: EFV plus 2 nucleoside analogues
Number of subjects: 39
Study: 25237119

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 43
Study: 23927483

Group type: EXPERIMENTAL
Intervention: 500-calorie well-balanced meal (WB500)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 250-calorie well-balanced meal (WB250)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 250-calorie high-fat meal (HF250)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 250-calorie well-balanced liquid meal (Ensure®)
Number of subjects: 32
Study: 21240871

Group type: EXPERIMENTAL
Intervention: ARB group (valsartan 40-80 mg daily for 6 months)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: ARB group
Number of subjects: 35
Study: 19406981

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg plus isoniazid placebo
Number of subjects: 328

Group type: COMPARATOR
Intervention: Isoniazid 300 mg plus moxifloxacin placebo
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Moxifloxacin group
Number of subjects: 328

Group type: COMPARATOR
Intervention: Isoniazid group
Number of subjects: 328
Study: 16505413

Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion (HAI)
Number of subjects: 135
Study: 12934979

Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg/day)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 211
Study: 10829320

Group type: EXPERIMENTAL
Intervention: Preoperative visualization therapy (Group A)
Number of subjects: 208

Group type: COMPARATOR
Intervention: No preoperative therapy (Group B)
Number of subjects: 208
Study: 8891847

Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon-alpha (5 MU/m2 thrice a week for 26 weeks)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon-alpha combined with deflazacort (6-week course)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Both groups (interferon alone and combined therapy)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon-alpha
Number of subjects: 38

Group type: COMPARATOR
Intervention: Non-responders
Number of subjects: 38
Study: 1381022

Group type: EXPERIMENTAL
Intervention: Isradipine 1.25 mg twice daily (b.i.d.)
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: Metoprolol 50 mg b.i.d.
Number of subjects: 876
Study: 6383655

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227